Research Paper Volume 13, Issue 10 pp 13859—13875

Figure 4. Curcumin inhibits AS plaque by decrease VSMCs proliferation and migration. (A, B) Analysis of percentage EdU-incorporated cells following curcumin treatment (48 h) for different durations. **, p< 0.01; ****, p< 0.0001. (C, D) Cell migration with or without curcumin treatment (20 μM, 24 h) as determined by wound healing assay. Percentage cell migration data are presented as means ± SDs. *, p< 0.05. (E) CCK-8 assessment of cell proliferation following treatment with curcumin (48 h) for different durations. *, p< 0.05; **, p< 0.01. (F) Schematic illustration of the establishment of a HFD ApoE^-/- mice model combined with curcumin treatment. HFD group, n = 8; curcumin (20 mg/kg/day), n = 8; curcumin (40 mg/kg/day), n = 8; curcumin (60 mg/kg/day), n = 8. (G, H) The lesion areas in aorta tissues of HFD ApoE^-/- mice with or without curcumin treatment. n.s., no significant; ***, p< 0.001. (I, J) IHC analysis of Ki-67 expression in aorta tissues of HFD ApoE^-/- mice with or without curcumin treatment. Scale bar = 100 μm. Red arrows indicate plaques. Ki-67 expression score analysis data are presented as means ± SDs. n.s., no significant; **, p< 0.01.